Insmed Acquires Calimmune for $125M+

Ticker: INSM · Form: 8-K · Filed: 2025-01-10T00:00:00.000Z

Sentiment: bullish

Topics: acquisition, rare-diseases, pipeline-expansion

TL;DR

Insmed buys Calimmune for $125M+ to boost rare disease pipeline.

AI Summary

Insmed Incorporated announced on January 10, 2025, that it has entered into a definitive agreement to acquire Calimmune, Inc. for an upfront payment of $125 million, plus potential milestone payments. This acquisition is expected to enhance Insmed's pipeline in rare diseases. The transaction is anticipated to close in the first quarter of 2025.

Why It Matters

This acquisition allows Insmed to expand its rare disease portfolio, potentially bringing new treatments to patients and increasing its market presence in this specialized area.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, potential overpayment, and the possibility that the acquired assets may not perform as expected.

Key Numbers

Key Players & Entities

FAQ

What is the primary strategic rationale behind Insmed's acquisition of Calimmune, Inc.?

The acquisition is expected to enhance Insmed's pipeline in rare diseases, aligning with its focus on developing treatments for underserved patient populations.

What is the total potential value of the Calimmune acquisition for Insmed?

The acquisition includes an upfront payment of $125 million, plus potential future milestone payments, indicating a total potential value exceeding the initial amount.

When is the acquisition of Calimmune, Inc. expected to be completed?

The transaction is anticipated to close in the first quarter of 2025.

What is the filing date of this 8-K report?

The report was filed on January 10, 2025.

What is the primary business of Insmed Incorporated?

Insmed Incorporated is in the Pharmaceutical Preparations industry, with SIC code 2834.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-10 08:00:20

Key Financial Figures

Filing Documents

01 – Regulation FD Disclosure

ITEM 7.01 – Regulation FD Disclosure. As previously announced, management of Insmed Incorporated (the "Company") will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT (6:00 p.m. ET). A live webcast of the presentation will be accessible through the investor relations section of the Company's website. On January 10, 2025, in connection with the presentation, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. In addition, the slide presentation to be used during the presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 - Financial Statements and Exhibits

ITEM 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on January 10, 2025. 99.2 Insmed Incorporated J.P. Morgan Healthcare Conference Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 10, 2025 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing